Literature DB >> 12810437

Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate.

T Skogh, D Gustafsson, M Kjellberg, M Husberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12810437      PMCID： PMC1754585          DOI： 10.1136/ard.62.7.681

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

2.  Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Authors:  Liseth Siemons; Harald E Vonkeman; Peter M ten Klooster; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-02-23       Impact factor: 2.980

Review 3.  Understanding emerging treatment paradigms in rheumatoid arthritis.

Authors:  Ferdinand C Breedveld; Bernard Combe
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

4.  Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors.

Authors:  Rodolfo A Kolliker Frers; Vanesa Cosentino; Julia Tau; Eduardo M Kerzberg; Adriana Urdapilleta; Monica Chiocconi; Nora Kogan; Matilde Otero-Losada; Francisco Capani
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

5.  Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.

Authors:  Kristopher A Standish; C Chris Huang; Mark E Curran; Nicholas J Schork
Journal:  Arthritis Res Ther       Date:  2017-05-12       Impact factor: 5.156

6.  Relationship Between Smoking and Structural Damage, Autoimmune Antibodies, and Disability in Rheumatoid Arthritis Patients.

Authors:  Filiz Sivas; Fatma Gül Yurdakul; Ayşegül Kiliçarslan; Semra Duran; Bedriye Başkan; Hatice Bodur
Journal:  Arch Rheumatol       Date:  2017-05-25       Impact factor: 1.472

Review 7.  Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.

Authors:  Paul Emery; Cem Gabay; Maarten Kraan; Juan Gomez-Reino
Journal:  Rheumatol Int       Date:  2007-05-16       Impact factor: 3.580

8.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

9.  Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.

Authors:  Michael J Cook; Janet Diffin; Carlo A Scirè; Mark Lunt; Alex J MacGregor; Deborah P M Symmons; Suzanne M M Verstappen
Journal:  Rheumatology (Oxford)       Date:  2016-05-24       Impact factor: 7.580
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.